[1]黄峻.中国心力衰竭流行病学特点和防治策略\[J\].中华心脏与心律电子杂志, 2015, 3(2):81-82.
[2]Davison BA, Metra M, Senger S, et al. Patient journey after admission for acute heart failure: length of stay,30day readmission and 90day mortality\[J\]. Eur J Heart Fail, 2016, 18(8):1041-1050.
[3]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018\[J\].中华心力衰竭和心肌病杂志, 2018, 2(4):196-225.
[4]Singh SC, Patnaik M, Sahoo SK, et al. Role of plasma Nterminal probrain natriuretic peptide (NTproBNP), a diagnostic and prognostic biomarker of acute dyspnea of cardiac diseases\[J\]. J Evol Med Dent Sci, 2017, 6(95):7030-7035.
[5]Vinnakota S, Scott CG, Rodeheffer RJ, et al. Estimated glomerular filtration rate, activation of cardiac biomarkers and longterm cardiovascular outcomes: A populationbased cohort\[J\]. Mayo Clinic Proc, 2019, 94(11):2189-2198.
[6]Feldreich T, Nowak C, Fall T, et al. Circulating proteins as predictors of cardiovascular mortality in endstage renal disease\[J\]. J Nephrol, 2019, 32(1):111-119.
[7]Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure\[J\]. J Card Fail, 2002, 8(3):149-154.
[8]Gelsomino S, Bonacchi M, Luca F, et al. Comparison between three different equations for the estimation of glomerular filtration rate in predicting mortality after coronary artery bypass\[J\]. BMC Nephrol, 2019, 20(1):13-21.
[9]姜文阳,李宜瑶.慢性心力衰竭患者血浆B型利钠肽水平反常正常化的研究进展\[J\].中国循环杂志, 2018, 33(7):720-722.
[10]Stoica A, Sorodoc V, Lionte C, et al. Acute cardiac dyspnea in the emergency department: diagnostic value of Nterminal prohormone of brain natriuretic peptide and galectin3\[J\]. J Int Med Res, 2019, 47(1):159-172.
[11]Davidovski FS, Goetze JP. ProANP and proBNP in plasma as biomarkers of heart failure\[J\]. Biomark Med, 2019, 13(13):1129-1135.
[12]孙英.NTproBNP在老年慢性心力衰竭患者诊治中的价值\[J\].心血管病防治知识, 2015(3):95-96.
[13]Dzidzic M, Petkowicz B, BednarekSkublewska A, et al. Relationship between renalase and Nterminal proBtype natriuretic peptide(NTproBNP) in haemodialysis patients\[J\]. Ann Agric Environ Med, 2014, 21(1):132-135.
[14]Pitt B, Bakris GL, Bushisky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors\[J\]. Eur J Heart Fail, 2015, 17(10): 1057-1065.
[15]Gergei I, Kramer BK, Scharnagl H, et al. Renal function, nterminal proBtype natriuretic peptide, propeptide bigendothelin and patients with heart failure and preserved ejection fraction\[J\]. Peptides, 2019, 111(51):112-117. |